

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2012 Army **DATE:** February 2011

APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>							
COST (\$ in Millions)	FY 2010	FY 2011	FY 2012 Base	FY 2012 OCO	FY 2012 Total	FY 2013	FY 2014	FY 2015	FY 2016	Cost To Complete	Total Cost
Total Program Element	32.851	28.132	34.997	-	34.997	23.291	18.736	18.894	21.191	Continuing	Continuing
808: <i>DOD DRUG & VACC AD</i>	6.655	7.225	11.569	-	11.569	9.354	9.240	9.459	11.902	Continuing	Continuing
811: <i>MIL HIV VAC&DRUG DEV</i>	1.410	2.923	2.348	-	2.348	1.188	0.808	0.824	0.835	Continuing	Continuing
836: <i>Field Medical Systems Advanced Development</i>	20.011	17.984	19.465	-	19.465	11.572	8.233	8.611	8.454	Continuing	Continuing
CS4: <i>MEDICAL SYSTEMS ADV DEV INITIATIVES (CA)</i>	4.775	-	-	-	-	-	-	-	-	Continuing	Continuing
VST: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV</i>	-	-	1.615	-	1.615	1.177	0.455	-	-	0.000	3.247

Note

A. Mission Description and Budget Item Justification

This program element (PE) funds development of medical materiel at the start of an official program of record, within the early system integration portion of the System Development and Demonstration phase of the acquisition life cycle using 6.4 funding. Program efforts support transition of promising Science and Technology candidate medical technologies (drugs, vaccines, medical devices, diagnostics, and mechanisms for detection and control of disease carrying insects) to larger scale testing in humans for safety and effectiveness. Programs are aligned to meet Future Force (F2) requirements stressed within concept documents and organizational structures. The PE provides funding for Food and Drug Administration (FDA) regulated human clinical trials to gain additional information about safety and effectiveness on the path to licensure for use in humans. The Projects supported by this PE are:

(PROJ 836) funds the demonstration and validation of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. This project also funds the human clinical trials that test the safety and effectiveness of biologics, devices and demonstration. Clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations. Products from this project will transition to 832.

(PROJ 808) funds development of candidate medical countermeasures for infectious diseases of military relevance. Efforts include vaccines, drugs, diagnostic kits/ devices, and insect control measures. These funds support human clinical efficacy trials of the drug/vaccine in a larger group that are designed to assess performance and to continue safety assessments in a larger group of volunteers. Products from this project will transition to 849.

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2012 Army	DATE: February 2011
---	----------------------------

APPROPRIATION/BUDGET ACTIVITY

2040: *Research, Development, Test & Evaluation, Army*
 BA 4: *Advanced Component Development & Prototypes (ACD&P)*

R-1 ITEM NOMENCLATURE

PE 0603807A: *Medical Systems - Adv Dev*

(PROJ 811) funds the development of military relevant human immunodeficiency virus (HIV) medical countermeasures. It provides funding for planning and conducting of human clinical trials in a group of healthy volunteers to assess the drug/vaccine for safety, tolerability, how the drug/vaccine is distributed, metabolized, and excreted from the body, and investigate the appropriate dose for therapeutic use. Products from this project will transition to Project 812.

(PROJ VS7) program upgrades, retrofits, trains, and sustains the 256 Medical Evacuation legacy helicopters that continue to play a major role in Iraq and Afghanistan. The force design will increase the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies to better meet operation needs. Products from this project will transition to VS8.

This program is managed by U.S. Army Medical Materiel Development Activity (USAMMDA) and U.S. Army Medical Materiel Agency (USAMMA) of the US Army Medical Research and Materiel Command

B. Program Change Summary (\$ in Millions)	<u>FY 2010</u>	<u>FY 2011</u>	<u>FY 2012 Base</u>	<u>FY 2012 OCO</u>	<u>FY 2012 Total</u>
Previous President's Budget	35.886	28.132	37.128	-	37.128
Current President's Budget	32.851	28.132	34.997	-	34.997
Total Adjustments	-3.035	-	-2.131	-	-2.131
• Congressional General Reductions		-			
• Congressional Directed Reductions		-			
• Congressional Rescissions	-	-			
• Congressional Adds		-			
• Congressional Directed Transfers		-			
• Reprogrammings	-2.099	-			
• SBIR/STTR Transfer	-0.936	-			
• Adjustments to Budget Years	-	-	-2.131	-	-2.131

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army								DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT 808: DOD DRUG & VACC AD			
COST (\$ in Millions)	FY 2010	FY 2011	FY 2012 Base	FY 2012 OCO	FY 2012 Total	FY 2013	FY 2014	FY 2015	FY 2016	Cost To Complete	Total Cost
808: DOD DRUG & VACC AD	6.655	7.225	11.569	-	11.569	9.354	9.240	9.459	11.902	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification											
This project funds development of candidate medical countermeasures for infectious diseases of military relevance. These efforts are in: vaccines, drugs, diagnostic kits/devices, and insect control measures. These funds support human clinical efficacy (capacity to produce a desired size of an effect under ideal or optimal conditions) trials of the drug/vaccine in larger groups that are designed to assess how well the drug/vaccine works, and to continue safety assessments in a larger group of volunteers. Funding supports both technical evaluations and human clinical testing to assure the safety and effectiveness of medical diagnostic kits and devices. This work, which is performed in military laboratories or civilian pharmaceutical firms, is directed toward the prevention of disease, early diagnosis, and speeding recovery once diagnosed. All clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations, a mandatory obligation for all military products placed into the hands of medical providers or service members. Product development priorities are determined based upon four major factors: (1) the extent and threat of the disease within the Combatant Commands theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development and production).											
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)								FY 2010	FY 2011	FY 2012	
Title: DoD Drug and Vaccine Advanced Development								6.655	7.225	11.569	
								Articles: 0	0		
Description: Funding is provided for the following effort											
FY 2010 Accomplishments:											
For Tafenoquine product, down-selected to best site for human safety/efficacy trial and continued laboratory assay development/validation to understand the human body's immune responses when infected with malaria parasites and as tool for determining future clinical trial enrollment size, and transition the entire Tafenoquine program to project 849. Monitored progress of a new military topical insect repellent candidate in project 810 to determine its suitability for entry into advanced development. For the Infectious Disease Diagnostic (multiple candidates), conducted market research of selected developmental and commercial diagnostic platforms for select infectious diseases of military interest to determine suitability for entry into advanced development. The Dengue Tetravalent Vaccine (DTV) vaccine continues FDA required vaccine potency and stability testing and all other DTV activities are transitioned to project 849 [Dengue is a severe debilitating disease caused by a virus and transmitted by a mosquito]. For the Topical Antileishmanial Cream [Leishmania is a skin-based disease caused by a parasite and transmitted by sand flies], continued a human treatment protocol in the U.S., the partner continued stability testing and produced new clinical drug lots, and project 849 supported the overseas human clinical trials activities of this topical cream. For Leishmania Skin Test (LST),											

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army		DATE: February 2011	
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 808: <i>DOD DRUG & VACC AD</i>	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)		FY 2010	FY 2011
<p>completed the final report for the expanded human safety dose ranging sensitization trial in the U.S., and conducted pre-trial activities for a large scale (>200 subjects) human safety/efficacy trial in a Leishmania endemic region.</p> <p>FY 2011 Plans: Prepare to accept transition of a new military topical insect repellent from project 810 at Milestone B into Engineering & Manufacturing Development phase. If candidate is ready transition new malaria vaccine candidate from project 810 into Engineering & Manufacturing Development phase. For the Infectious Disease Diagnostic (multiple candidates), prepare to accept transition of project into the Engineering & Manufacturing Development phase of advanced development. The DTV vaccine will continue FDA required vaccine potency and stability testing and all other DTV activities are transitioned to project 849. For Topical Antileishmanial Cream, continue a human treatment protocol in the US, the industry partner continues stability testing of the drug product, and project 849 supports the overseas human trials activities of the topical cream.</p> <p>FY 2012 Plans: Review evaluations, and human clinical trials of malarial/anti-malarial drugs, vaccines, diagnostics, insect repellents, and grouped infectious disease (Dengue [a severe debilitating disease caused by a virus and transmitted by a mosquito] and Leishmania [a skin-based disease caused by a parasite and transmitted by sand flies]) vaccines, drugs and diagnostics. Will seek industry partner and evaluate and complete down-selection of drug candidates for human trials for prevention or treatment of malaria. Will continue to evaluate the vaccine candidate for dengue with industry partner Sanofi Pasteur. For Topical Antileishmanial Cream, will continue a human treatment protocol in the US, the industry partner continues stability testing of the drug product, and project 849 supports the overseas human trials activities of the topical cream.</p>			
Accomplishments/Planned Programs Subtotals		6.655	7.225
C. Other Program Funding Summary (\$ in Millions)			
N/A			
D. Acquisition Strategy			
Test and evaluate in-house and commercially developed products in extensive government-managed clinical trials to gather data required for FDA licensure and Environmental Protection Agency registration.			
E. Performance Metrics			
Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.			

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2012 Army											DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT 808: DOD DRUG & VACC AD						
Management Services (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
No product/contract costs greater than \$1M individually	Various	Not Applicable:Not applicable	9.316	1.530		1.250		-		1.250	Continuing	Continuing	Continuing	
Subtotal			9.316	1.530		1.250		-		1.250				
Product Development (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
No product/contract costs greater than \$1M individually	Various	Not applicable:Not applicable	9.114	1.819		8.269		-		8.269	Continuing	Continuing	Continuing	
Subtotal			9.114	1.819		8.269		-		8.269				
Support (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
No product/contract costs greater than \$1M individually	Various	Not Applicable:Not applicable	3.820	1.495		1.250		-		1.250	Continuing	Continuing	Continuing	
Subtotal			3.820	1.495		1.250		-		1.250				
Test and Evaluation (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
No product/contract costs greater than \$1M individually	Various	Not applicable:Not applicable	38.363	2.381		0.800		-		0.800	Continuing	Continuing	Continuing	
Subtotal			38.363	2.381		0.800		-		0.800				

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2012 Army								DATE: February 2011						
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT 808: DOD DRUG & VACC AD						
				Total Prior Years Cost	FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals				60.613	7.225		11.569		-		11.569			

Remarks

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2012 Army			DATE: February 2011		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>		R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>		PROJECT 808: <i>DOD DRUG & VACC AD</i>	

	FY 2010				FY 2011				FY 2012				FY 2013				FY 2014				FY 2015				FY 2016			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
New Standard Military Topical Insect Repellant (MS-B)																												
Anti-Malarial drug candidates Product Design Review (PDR)																												
Leishmania Skin Test CDR																												

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2012 Army			DATE: February 2011
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 808: <i>DOD DRUG & VACC AD</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
New Standard Military Topical Insect Repellant (MS-B)	1	2011	1	2011
Anti-Malarial drug candidates Product Design Review (PDR)	1	2011	1	2011
Leishmania Skin Test CDR	2	2011	2	2011

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army								DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 811: <i>MIL HIV VAC&DRUG DEV</i>			
COST (\$ in Millions)	FY 2010	FY 2011	FY 2012 Base	FY 2012 OCO	FY 2012 Total	FY 2013	FY 2014	FY 2015	FY 2016	Cost To Complete	Total Cost
811: <i>MIL HIV VAC&DRUG DEV</i>	1.410	2.923	2.348	-	2.348	1.188	0.808	0.824	0.835	Continuing	Continuing
Quantity of RDT&E Articles											

A. Mission Description and Budget Item Justification

This project funds development of militarily relevant human immunodeficiency virus (HIV) medical countermeasures. It provides funding for the planning and conducting of human clinical trials in a group of healthy volunteers to assess the drug/vaccine for safety, tolerability, how the drug/vaccine is distributed, metabolized, and excreted from the body, and to investigate the appropriate dose for therapeutic use. Development efforts are focused on militarily unique needs effecting manning, mobilization, and deployment.

The major contractor is Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD. Research efforts are coordinated with the National Institutes of Health.

B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)	FY 2010	FY 2011	FY 2012
Title: Military HIV Vaccine & Drug Development Articles: Description: Funding is provided for the following effort FY 2010 Accomplishments: Evaluated and down-select drug/vaccine candidates for preliminary human trials and conduct Design Readiness Review (DRR). FY 2011 Plans: Seek new industry partnership for selected candidate(s) drug/vaccine for HIV medical treatment/prevention. FY 2012 Plans: Perform three inter-related studies to enhance our understanding of precisely how the vaccine strategy used in the safety/efficacy trial completed in 2009 caused vaccine recipients to be protected from infection, including intense laboratory studies using samples from the trial, and commencement of two small clinical vaccine trials to generate data and samples to hopefully define what vaccine responses to try to generate for next increment studies.	1.410 0	2.923 0	2.348
Accomplishments/Planned Programs Subtotals	1.410	2.923	2.348

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army		DATE: February 2011
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 811: <i>MIL HIV VAC&DRUG DEV</i>
C. Other Program Funding Summary (\$ in Millions) N/A		
D. Acquisition Strategy Test and evaluate commercially developed drug/vaccine candidates in government-managed trials.		
E. Performance Metrics Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.		

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2012 Army											DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT 811: MIL HIV VAC&DRUG DEV						
Management Services (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
No product/contract costs greater than \$1M individually.	TBD	Not Applicable:Not Applicable	0.456	0.473		0.473		-		0.473	Continuing	Continuing	Continuing	
Subtotal			0.456	0.473		0.473		-		0.473				
Remarks Not Applicable														
Product Development (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
No product/contract costs greater than \$1M individually	Various	Not applicable:Not applicable	1.215	0.746		0.360		-		0.360	Continuing	Continuing	Continuing	
Subtotal			1.215	0.746		0.360		-		0.360				
Support (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
No product/contract costs greater than \$1M individually	TBD	Not applicable:Not Applicable	1.215	0.597		0.408		-		0.408	Continuing	Continuing	Continuing	
Subtotal			1.215	0.597		0.408		-		0.408				
Remarks Not Applicable														

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2012 Army											DATE: February 2011		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 811: <i>MIL HIV VAC&DRUG DEV</i>					

Test and Evaluation (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Test and Evaluation	TBD	U.S. Component AFRIMS.;Bangkok	12.200	1.107		1.107		-		1.107	Continuing	Continuing	Continuing
Subtotal			12.200	1.107		1.107		-		1.107			

Remarks Not Applicable													
----------------------------------	--	--	--	--	--	--	--	--	--	--	--	--	--

	Total Prior Years Cost	FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	15.086	2.923		2.348		-		2.348			

Remarks											
----------------	--	--	--	--	--	--	--	--	--	--	--

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2012 Army	DATE: February 2011
--	----------------------------

APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 811: <i>MIL HIV VAC&DRUG DEV</i>
---	---	--

	FY 2010				FY 2011				FY 2012				FY 2013				FY 2014				FY 2015				FY 2016			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
HIV Vaccine Design Readiness Review (DRR)																												
RV305 Phase 2 Study of Secondary Boost																												
RV306 Phase 2 Study																												
RV3XX ALVAC vs NYVAC Phase 2 Study																												
Prime/Boost Phase 3 Study																												

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2012 Army			DATE: February 2011
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 811: <i>MIL HIV VAC&DRUG DEV</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
HIV Vaccine Design Readiness Review (DRR)	3	2010	3	2010
RV305 Phase 2 Study of Secondary Boost	1	2011	3	2013
RV306 Phase 2 Study	1	2011	3	2013
RV3XX ALVAC vs NYVAC Phase 2 Study	4	2011	3	2014
Prime/Boost Phase 3 Study	4	2014	3	2016

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army								DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT 836: Field Medical Systems Advanced Development			
COST (\$ in Millions)	FY 2010	FY 2011	FY 2012 Base	FY 2012 OCO	FY 2012 Total	FY 2013	FY 2014	FY 2015	FY 2016	Cost To Complete	Total Cost
836: Field Medical Systems Advanced Development	20.011	17.984	19.465	-	19.465	11.572	8.233	8.611	8.454	Continuing	Continuing
Quantity of RDT&E Articles											
Note In FY10 Project 837 Soldier Sys Prot-AD has been consolidated into this Project, 836. Major contractors/intra-governmental agencies include: IGR Enterprises, Inc.; Army Medical Department Board Test Center; SeQual Technologies, Inc.; Ultrasonic Diagnostics, Inc.; HemCon Medical Technologies, Inc.; Hemerus Medical, LLC.; Fast Track Drugs & Biologics, LLC; Clinical Research Management, and Walter Reed Army Institute of Research (WRAIR) and Institute of Surgical Research (ISR) for user evaluation. Other military agencies include Program Executive Office (PEO) Soldier, PEO Combat Service Support, and Naval Undersea Warfare Center.											
A. Mission Description and Budget Item Justification This project funds the demonstration and validation of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. This project funds human clinical trials to test the safety and effectiveness of biologics (products derived from living organisms) and devices necessary to meet medical requirements. When available, commercial-off-the-shelf (COTS) medical products are also tested and evaluated for transition to system development and demonstration. Consideration is also given to reducing the medical logistics footprint through smaller weight, volume, and equipment independence from supporting materials. All clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations.											
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)								FY 2010	FY 2011	FY 2012	
Title: Field Medical Systems Advanced Development Articles: Description: Funding is provided for the following effort FY 2010 Accomplishments: Conducted human trials to assess intranasal ketamine drug effects on a subject's judgment. Antiplateque Gum: transitioned from project 840 and conducted a small human safety and dose escalation study in health adults. Environmental Sentinel Biomonitor (ESB): transitioned increment 1 from project 837 and increment 2 from technology development project FH4, initiated development of increment 2 ESB system for use in conjunction with field water facilities. Field tested one Ceramic Oxygen Generator system for the Force Provider Early Entry Combat Support Hospital (CSH). Transitioned Ultrasonic brain Imager product to project 832 for Systems Development and Demonstration. FY 2011 Plans:								20.011	17.984	-	
								0	0		

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army			DATE: February 2011		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>		R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>		PROJECT 836: <i>Field Medical Systems Advanced Development</i>	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)			FY 2010	FY 2011	FY 2012
Total Intravenous Anesthesia (TIVA): Perform clinical trials and submit required documents for FDA clearance/approval. Auto Critical Care System (ACCLS): Conduct validation testing and Army DT/OT/AWC. Submit the 510K for FDA review for modified devices. Urinary Facilitation Device: Testing, reports, and review for FDA approval. PEAK Surgical System (Plasma Blade): if preclinical results are favorable, conduct environmental testing and identify any needed design modifications to produce a fieldable unit. Pursue additional regulatory approvals as needed. Plasma Knife: if preclinical results are favorable, conduct environmental testing and identify any needed design modifications to produce a fieldable unit. Pursue additional regulatory approvals as needed. Hydrosurgery System: Conduct operational and environmental testing. Remote Diagnostic Access (RDA): Develop software, conduct testing, and refinement for MOC Sensor Modul Development phase. Treatment Table for PM, HBCT Medical Mission Package for Treatment Variants: Transition to Project 832. Refrigerator for PM, HBCT for Medical Mission Package for Treatment Variant: Transition to Project 832. Shock and Vibration Isolation System for Patient Litters in Ground and Air Medical Evacuation Vehicles: Transition to Project 832. Shelter for PM, HBCT for Medical Mission Package for Treatment Variant: Transition to Project 832. Passive Cold Chain Capability for Temperature Sensitive Medical Materiel: Transition to Project 832. The intranasal ketamine drug effects study transition to project 832 for Systems Development and Demonstration.					
Title: Field Medical Systems Advanced Development - PM Medical Devices Description: Funding is provided for the following effort FY 2012 Plans: Non-invasive Multi-Analyte Monitor submission for RFP in 2QFY12 for the use of Infra Red Spectrometry to assess analyte concentration in blood. Hydration Meter: will conduct validation testing in 4Q. Plasma Knife: Will transition product to 6.5 funding in PE 832 line. Eye Tracking System for Assessing Concussions is a traumatic brain injury diagnostic tool that begins clinical trial to move to FDA submission in 1Q FY. Fibrinogen Bandages will use an antimicrobial irrigation solution to protect blast injury wound sites from bacterial infection. 2Q FY12 final review of Good Manufacturing Practice (GMP) will be conducted for movement forward to FDA submission. Cardiopulmonary Enhancement: conduct multiple collaborative clinical protocols to review arrest and life threatening trauma devices for enhanced treatment.			-	-	7.428
Title: Field Medical Systems Advanced Development - PM Pharmaceuticals Description: Funding is provided for the following effort FY 2012 Plans: Cryopreserved Platelets (CPP) (use of cryopreserved platelets for control of severe bleeding): Will conduct clinical safety evaluations and conduct good manufacturing practices preliminary validation studies of the product. The Freeze-dried Plasma			-	-	7.759

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army		DATE: February 2011	
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 836: <i>Field Medical Systems Advanced Development</i>	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)		FY 2010	FY 2011
(FDP) Program (hemorrhage treatment candidate): Will conduct preliminary clinical evaluations and conduct good manufacturing practices preliminary validation studies.			
Title: Field Medical systems Advanced Development - PM Integrated Clinical Systems (ICS) Description: Funding is provided for the following effort FY 2012 Plans: Will conduct final testing of Phase IV of the Remote Diagnostic Access (RDA). Will Develop a universal security compliant access portal to serve as a standardized compliance wrapper for all vendors, medical technology, and even IT management products that may traverse between the .com and .mil networks. The Milestone Decision Authority (MDA) is scheduled to review the RDA project in March 2011 for continuation or termination.		-	0.888
Title: Field Medical Systems Advanced Development - PM Medical Support Systems Description: Funding is provided for the following effort FY 2012 Plans: Treatment Table and Blood Refrigerator prototypes for PM HBCT will be finished and prepared for testing. Shock and Vibration Litter Isolation data analysis will be presented to the MDA for decision to transition to 832. New cold chain technologies will be explored for MES set inclusion. Quad fold litter, litter straps, and hands-free litter system from RFIs will continue to be explored and transition to 832. New ISO shelter panels will be tested in FY12 and transitioned back into ISO shelter specification for future shelter buys. Testing of Trauma Tiered Medical Bag will be accomplished and transition to PEP soldier. Soft-walled shelter development will continue to finalize Force Provider modules for use in Combat Support Hospitals. Prototype Water and Waste Water Management system will be developed and transitioned to 832 for testing.		-	3.390
Accomplishments/Planned Programs Subtotals		20.011	19.465
C. Other Program Funding Summary (\$ in Millions)			
N/A			
D. Acquisition Strategy			
Develop in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding.			
E. Performance Metrics			
Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.			

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2012 Army										DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT 836: Field Medical Systems Advanced Development					
Management Services (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$M individually.	Various	Not Applicable:Not applicable	33.721	0.944		2.540		-		2.540	Continuing	Continuing	Continuing
Subtotal			33.721	0.944		2.540		-		2.540			
Product Development (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Product Development	C/FFP	Clinical Research Management:Hinckley, Ohio	-	1.133		-		-		-	Continuing	Continuing	Continuing
Product Development	TBD	Allied Technologies & Consulting LLC:Frederick, MD	3.365	2.000		-		-		-	Continuing	Continuing	Continuing
Product Development	TBD	Aquila Alaska Corporation:Aquila Alaska	1.200	-		-		-		-	Continuing	Continuing	Continuing
Product Development	Various	HemCon Medical Technologies:Tigard, Oregon	-	-		8.000		-		8.000	0.000	8.000	0.000
Product Development	Various	Not Applicable:Not Applicable	20.618	-		-		-		-	Continuing	Continuing	Continuing
Development of Platelet Derived Hemostatic agent	Various	Fast Track Drugs & Biologics:Frederick, MD	-	-		1.500		-		1.500	0.000	1.500	0.000
Product Development	Various	ALL Product:Various	-	-		1.000		-		1.000	0.000	1.000	0.000
Subtotal			25.183	3.133		10.500		-		10.500			

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2012 Army											DATE: February 2011		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 836: <i>Field Medical Systems Advanced Development</i>					

Support (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$M individually.	Various	Not Applicable:Not applicable	33.721	5.253		0.969		-		0.969	Continuing	Continuing	Continuing
Subtotal			33.721	5.253		0.969		-		0.969			

Remarks No product/contract costs greater than \$1M individually.													
---	--	--	--	--	--	--	--	--	--	--	--	--	--

Test and Evaluation (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1 Million individually.	C/UCA	Not applicable:Not applicable	13.091	8.654		5.456		-		5.456	Continuing	Continuing	Continuing
Subtotal			13.091	8.654		5.456		-		5.456			

Remarks No product/contract costs greater than \$1M individually.													
---	--	--	--	--	--	--	--	--	--	--	--	--	--

			Total Prior Years Cost	FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals			105.716	17.984		19.465		-		19.465			

Remarks													
----------------	--	--	--	--	--	--	--	--	--	--	--	--	--

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2012 Army			DATE: February 2011		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>		R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>		PROJECT 836: <i>Field Medical Systems Advanced Development</i>	

	FY 2010				FY 2011				FY 2012				FY 2013				FY 2014				FY 2015				FY 2016			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Antiplatelet Gum: Safety Study																												
Total intravenous Anesthesia (TIVA): Clinical Trials																												
Fibrinogen Bandages																												
Cryopreserved Platelets Critical Design Review MS-B																												
Freeze-Dried Plasma MS-B																												
Non-invasive Multi-Analyte Monitor																												
Hydration Meter																												
Eye Tracking System for Assessment of Concussions																												

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2012 Army			DATE: February 2011
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 836: <i>Field Medical Systems Advanced Development</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Antiplatelet Gum: Safety Study	3	2010	4	2010
Total intravenous Anesthesia (TIVA): Clinical Trials	3	2011	3	2011
Fibrinogen Bandages	3	2012	3	2012
Cryopreserved Platelets Critical Design Review MS-B	3	2011	4	2011
Freeze-Dried Plasma MS-B	1	2012	1	2012
Non-invasive Multi-Analyte Monitor	1	2012	1	2012
Hydration Meter	3	2012	3	2012
Eye Tracking System for Assessment of Concussions	4	2011	4	2011

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army								DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT CS4: MEDICAL SYSTEMS ADV DEV INITIATIVES (CA)			
COST (\$ in Millions)	FY 2010	FY 2011	FY 2012 Base	FY 2012 OCO	FY 2012 Total	FY 2013	FY 2014	FY 2015	FY 2016	Cost To Complete	Total Cost
CS4: MEDICAL SYSTEMS ADV DEV INITIATIVES (CA)	4.775	-	-	-	-	-	-	-	-	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification Congressional Interest Item funding for medical systems advanced development initiatives.											
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)								FY 2010	FY 2011	FY 2012	
Title: Wireless Medical Monitoring System Articles: Description: This is a Congressional Interest Item. FY 2010 Accomplishments: Conducted advanced development research in Wireless Medical Monitoring System								2.400	-	-	
								0			
Title: Quality Systems Program for FDA Regulation Activities Articles: Description: This is a Congressional Interest Item. FY 2010 Accomplishments: Conducted advanced development research of a Quality Systems Program for FDA Regulation Activities								1.175	-	-	
								0			
Title: Model for Green Laboratories and Clean Rooms Articles: Description: This is a Congressional Interest Item. FY 2010 Accomplishments: Conducted advanced development research and study for a Model for Green Laboratories and Clean Rooms								1.200	-	-	
								0			
Accomplishments/Planned Programs Subtotals								4.775	-	-	

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army		DATE: February 2011
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT CS4: <i>MEDICAL SYSTEMS ADV DEV INITIATIVES (CA)</i>
C. Other Program Funding Summary (\$ in Millions) N/A		
D. Acquisition Strategy N/A		
E. Performance Metrics Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.		

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army								DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT VS7: MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV			
COST (\$ in Millions)	FY 2010	FY 2011	FY 2012 Base	FY 2012 OCO	FY 2012 Total	FY 2013	FY 2014	FY 2015	FY 2016	Cost To Complete	Total Cost
VS7: MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV	-	-	1.615	-	1.615	1.177	0.455	-	-	0.000	3.247
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification											
Original models of Army Black Hawk MEDEVAC helicopters continue to play a major role in maintaining high US troop survival rates in Iraq and Afghanistan by evacuating wounded troops in less than one-hour. In 2009 a VCSA-approved force design update increased the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies to better meet operational needs. In 2010, the AMEDD accepted life-cycle management of the MEDEVAC MEP from PEO Aviation. In order to achieve required operational capability and enhance commonality across the MEDEVAC fleet, the MEDEVAC MEP program upgrades, retrofits, trains, and sustains the 256 MEDEVAC legacy helicopters to achieve the medical capability provided by the HH-60M, which is factory built for the MEDEVAC mission.											
B. Accomplishments/Planned Programs (\$ in Millions)								FY 2010	FY 2011	FY 2012	
Title: MEDEVAC Mission Sensor Foward Looking Infrared (FLIR)								-	-	0.575	
Description: Funding is provided for the following effort											
FY 2012 Plans: MEDEVAC Mission Sensor (MMS) FLIR for UH-60 aircraft. One of the requirements for the UH-60A/L MEDEVAC is a sensor system that will assist the pilots in locating patient pick-up points and assist them in maintaining situational awareness in night and adverse weather conditions. The MMS is currently being qualified for use on the HH-60M aircraft. This system will be installed on UH-60 aircraft using the proven Sponson-Mount FLIR system, which is currently being used in OEF for the MEDEVAC mission. The funds will develop and test a Medical Mission Sensor FLIR prototype on the UH-60A/L.											
Title: Environmental Control System for MEDEVAC aircraft								-	-	0.509	
Description: Funding is provided for the following effort											
FY 2012 Plans: The HH-60A/L/M has an environmental control system to assist in regulating the cabin temperature. This system will help prevent injury and loss of life to patients due to heat stress or hypothermia during transport. The system will also provide improved crew comfort in extreme environmental conditions, particularly high temperatures. The system will utilize the component-qualified 2-Pallet ECS developed for the HH-60M and develop and test a prototype installation for the UH-60A/L.											
Title: Telemedicine for MEDEVAC aircraft								-	-	0.531	

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army		DATE: February 2011	
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT VST: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV</i>	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2010	FY 2011
Description: Funding is provided for the following effort FY 2012 Plans: Telemedicine is an on going requirement for US Army MEDEVAC, to allow the patient care-giver at point of injury or during transport to access the knowledge and expertise of a more qualified care-giver at a remote location, and to provide patient data to the receiving facility prior to patient arrival, allowing the facility more time to prepare for intensive care patients. The program will develop, install, and test a telemedicine system for the UH-60A/L family of aircraft.			
Accomplishments/Planned Programs Subtotals		-	1.615
C. Other Program Funding Summary (\$ in Millions)			
N/A			
D. Acquisition Strategy			
Develop in-house or industrial prototypes in government-managed programs to meet military MEDEVAC and regulatory requirements for production and fielding.			
E. Performance Metrics			
Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.			

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2012 Army											DATE: February 2011		
APPROPRIATION/BUDGET ACTIVITY				R-1 ITEM NOMENCLATURE				PROJECT					
2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				PE 0603807A: Medical Systems - Adv Dev				VST: MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV					
Management Services (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1 Million individually	TBD	APM MEDEVAC PEO Aviation:Huntsville, AL	-	-		0.176		-		0.176	0.000	0.176	0.000
Subtotal			-	-		0.176		-		0.176	0.000	0.176	0.000
Product Development (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1Million individually	Various	APM MEDEVAC PEO Aviation:Huntsville, AL	-	-		1.140		-		1.140	0.000	1.140	0.000
Subtotal			-	-		1.140		-		1.140	0.000	1.140	0.000
Support (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	TBD	APM MEDEVAC PEO Aviation:Huntsville, AL	-	-		0.100		-		0.100	0.000	0.100	0.000
Subtotal			-	-		0.100		-		0.100	0.000	0.100	0.000
Test and Evaluation (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1Million individually	TBD	APM MEDEVAC PEO Aviation:Huntsville, AL	-	-		0.199		-		0.199	0.000	0.199	0.000
Subtotal			-	-		0.199		-		0.199	0.000	0.199	0.000

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2012 Army									DATE: February 2011					
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT VST: MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV						
				Total Prior Years Cost	FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals				-	-		1.615		-		1.615	0.000	1.615	0.000

Remarks

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2012 Army			DATE: February 2011		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>			R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>		
			PROJECT VST: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV</i>		

	FY 2010				FY 2011				FY 2012				FY 2013				FY 2014				FY 2015				FY 2016			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
MEDEVAC Mission Sensor (MMS) FLIR																												
Environmental Control System																												
Telemedicine																												

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2012 Army			DATE: February 2011
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT VST: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
MEDEVAC Mission Sensor (MMS) FLIR	4	2011	4	2011
Environmental Control System	4	2011	4	2011
Telemedicine	4	2011	1	2012